Other drugs targeting MAPK such as ERK1/2 inhibitor ulixertinib have also shown potent activity in clinical trials including colon cancer, gallbladder adenocarcinoma, glioblastoma and other solid tumors 62. The gene discussed is MAPK3; the disease is gallbladder adenocarcinoma.